Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
While frontline triplet therapies have shown improved efficacy over doublets with tolerable safety, doublet use remains in older and frail patients, creating an opportunity to improve outcomes in this particular patient population.
Authors
- Matthew J. Pianko (ORCID: https://orcid.org/0000-0001-9295-9750)
- Bruno Émond (ORCID: https://orcid.org/0000-0002-0060-765X)
- Annelore Cortoos
- Niodita Gupta‐Werner
- Patrick Lefèbvre (ORCID: https://orcid.org/0000-0002-2216-5442)
- Marie-Hélène Lafeuille
- Shuchita Kaila
Institutions
- Johnson & Johnson (United States) (US)
- University of Michigan (US)
Publication Details
- Journal
- Future Science OA
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1080/20565623.2025.2528523
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00